Oral Paclitaxel Improves Response, Reduces Peripheral Neuropathy in Metastatic Breast Cancer
December 18th 2019Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.
Read More
MRD Measurement Shows Promise for Making Informed Treatment Decisions in Myeloma
December 15th 2019At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.
Read More
Menopausal Hormone Therapy with Estrogen Alone Decreases Breast Cancer Incidence
December 14th 2019Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.
Read More
Arimidex Extends Benefit of Breast Cancer Recurrence Prevention in Postmenopausal Women
December 13th 2019Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.
Read More
Adding S-1 to Endocrine Therapy Improves Survival in Japanese Patients with Breast Cancer
December 12th 2019Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.
Read More
Addition of Perjeta to Standard Care Improves Survival in HER2-Positive Early Breast Cancer
December 12th 2019Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.
Read More